Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）

This is the prospective, observational cohort study (Radiogenomics-Urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic cancer patients.

Study Overview

• Status: Recruiting
• Conditions: Urologic Cancer

• Study Type: Observational
• Enrollment (Estimated): 150

Contacts and Locations

• Study Contact: Name: Lian Yang; Phone Number: 18986273791; Email: yanglian@hust.edu.cn

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430000
      • Recruiting
      • Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
      • Contact: Lian Yang; Phone Number: 18986273791; Email: yanglian@hust.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients treated for urologic cancer

Description

Inclusion Criteria:

1. Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027;
2. Aged > 18 years old;
3. At least one CT scan or MRI scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria：

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than urologic cancer;
4. Unclear pathological diagnosis。

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation analysis of sequencing results and body composition	Conducting correlation analysis between body composition and results of multi-omics sequencing.	0.5 year
Correlation analysis of sequencing results and tumor radiomic features	Conducting correlation analysis between radiomic features and results of multi-omics sequencing.	0.5 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Constructing tumor microenvironment prediction model	Constructing radiomic model to predict tumor microenvironment. The indicator is the area under the curve (AUC) of the prediction model	2 years
Constructing a multi-dimensional prognostic prediction model	A high-dimensional model was constructed to predict the prognosis of patients through multi-omics sequencing data, body composition, and tumor radiomic features. The indicator is the area under the curve (AUC) of the prediction model.	3 years

Collaborators and Investigators

• Sponsor: Wuhan Union Hospital, China

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2024
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): August 1, 2027

Study Registration Dates

• First Submitted: July 31, 2024
• First Submitted That Met QC Criteria: July 31, 2024
• First Posted (Estimated): August 5, 2024

Study Record Updates

• Last Update Posted (Estimated): August 5, 2024
• Last Update Submitted That Met QC Criteria: July 31, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Urologic Neoplasms
• Other Study ID Numbers: S187

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No